FR22C1013I2 - Dihydronaphtyridines et composés apparentés utiles comme inhibiteurs de kinases pour le traitement de maladies prolifératives - Google Patents
Dihydronaphtyridines et composés apparentés utiles comme inhibiteurs de kinases pour le traitement de maladies proliférativesInfo
- Publication number
- FR22C1013I2 FR22C1013I2 FR22C1013C FR22C1013C FR22C1013I2 FR 22C1013 I2 FR22C1013 I2 FR 22C1013I2 FR 22C1013 C FR22C1013 C FR 22C1013C FR 22C1013 C FR22C1013 C FR 22C1013C FR 22C1013 I2 FR22C1013 I2 FR 22C1013I2
- Authority
- FR
- France
- Prior art keywords
- dihydronaphtyridines
- treatment
- kinase inhibitors
- compounds useful
- related compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17208408.9A EP3366293B1 (en) | 2012-06-07 | 2012-06-07 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| PCT/US2012/041378 WO2013184119A1 (en) | 2012-06-07 | 2012-06-07 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR22C1013I1 FR22C1013I1 (fr) | 2022-06-17 |
| FR22C1013I2 true FR22C1013I2 (fr) | 2022-12-30 |
Family
ID=49712374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR22C1013C Active FR22C1013I2 (fr) | 2012-06-07 | 2022-04-07 | Dihydronaphtyridines et composés apparentés utiles comme inhibiteurs de kinases pour le traitement de maladies prolifératives |
Country Status (26)
| Country | Link |
|---|---|
| EP (3) | EP3366293B1 (pt) |
| JP (1) | JP5883195B2 (pt) |
| KR (1) | KR101652229B1 (pt) |
| CN (3) | CN110403938A (pt) |
| AU (1) | AU2012327210B2 (pt) |
| BR (1) | BR112014030577B1 (pt) |
| CA (1) | CA2875970C (pt) |
| CY (1) | CY1123377T1 (pt) |
| DK (2) | DK3366293T3 (pt) |
| ES (2) | ES2797252T3 (pt) |
| FR (1) | FR22C1013I2 (pt) |
| HK (1) | HK1209345A1 (pt) |
| HR (1) | HRP20200864T1 (pt) |
| HU (2) | HUE049958T2 (pt) |
| IL (1) | IL236110A (pt) |
| LT (2) | LT3366293T (pt) |
| MX (2) | MX2020005712A (pt) |
| NO (1) | NO2022010I1 (pt) |
| PH (2) | PH12014502757B1 (pt) |
| PL (1) | PL3366293T3 (pt) |
| PT (2) | PT3366293T (pt) |
| RS (1) | RS60406B1 (pt) |
| RU (1) | RU2664055C2 (pt) |
| SG (1) | SG11201408133TA (pt) |
| SI (1) | SI3366293T1 (pt) |
| WO (1) | WO2013184119A1 (pt) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| MY181020A (en) | 2013-03-15 | 2020-12-16 | Sanofi Sa | Heteroaryl compounds and uses thereof |
| US9321786B2 (en) | 2013-03-15 | 2016-04-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| BR112015022191A8 (pt) | 2013-03-15 | 2018-01-23 | Celgene Avilomics Res Inc | compostos heteroarila e usos dos mesmos |
| SI3402792T1 (sl) * | 2016-01-11 | 2022-01-31 | Merck Patent Gmbh | Derivati kinolin-2-ona |
| MX2019014343A (es) * | 2017-05-30 | 2020-08-03 | Deciphera Pharmaceuticals Inc | Uso de 1-[4-bromo-5-[1-etil-7-(metilamino)-2-oxo-1,2-dihidro-1,6-n aftiridin-3-il]-2-fluorofenil]-3-fenilurea y analogos para el tratamiento de canceres asociados con anomalias geneticas en el receptor alfa del factor de crecimiento derivado de plaquetas. |
| CN111094286B (zh) * | 2017-09-20 | 2022-07-29 | 浙江海正药业股份有限公司 | 1,2-二氢-1,6-萘啶类衍生物、其制备方法及其在医药上的用途 |
| SG11202007198WA (en) * | 2018-01-31 | 2020-08-28 | Deciphera Pharmaceuticals Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
| CA3089630A1 (en) | 2018-01-31 | 2019-08-08 | Deciphera Pharmaceuticals, Llc | Combination therapy for the treatment of mastocytosis |
| WO2020185812A1 (en) * | 2019-03-11 | 2020-09-17 | Teva Pharmaceuticals International Gmbh | Solid state forms of ripretinib |
| EP3962484A4 (en) | 2019-05-03 | 2023-01-18 | Kinnate Biopharma Inc. | RAF KINASE INHIBITORS |
| EP4013412A1 (en) | 2019-08-12 | 2022-06-22 | Deciphera Pharmaceuticals, LLC | Ripretinib for treating gastrointestinal stromal tumors |
| TW202122082A (zh) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| EP4048259A4 (en) | 2019-10-24 | 2023-08-02 | Kinnate Biopharma Inc. | RAF KINASE INHIBITORS |
| EP4084779B1 (en) | 2019-12-30 | 2024-10-09 | Deciphera Pharmaceuticals, LLC | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| EP4084778B1 (en) | 2019-12-30 | 2023-11-01 | Deciphera Pharmaceuticals, LLC | Amorphous kinase inhibitor formulations and methods of use thereof |
| KR102535840B1 (ko) * | 2020-07-31 | 2023-05-23 | (주)파로스아이바이오 | 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도 |
| WO2022060996A1 (en) | 2020-09-18 | 2022-03-24 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| WO2022081469A1 (en) | 2020-10-12 | 2022-04-21 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| CN112625038A (zh) * | 2020-12-31 | 2021-04-09 | 武汉九州钰民医药科技有限公司 | 制备瑞普替尼的方法 |
| WO2022162690A1 (en) * | 2021-01-28 | 2022-08-04 | Dr. Reddy's Laboratories Limited | Process for the preparation of ripretinib and solid state forms thereof |
| JP2024516972A (ja) | 2021-04-23 | 2024-04-18 | キネート バイオファーマ インク． | Ｒａｆ阻害薬による癌の処置 |
| WO2023122322A1 (en) * | 2021-12-24 | 2023-06-29 | Teva Pharmaceuticals International Gmbh | Improved processes for the preparation of ripretinib |
| CN114213411B (zh) * | 2022-01-24 | 2023-06-30 | 成都伊诺达博医药科技有限公司 | 一种瑞普替尼的合成方法 |
| WO2023150681A1 (en) | 2022-02-03 | 2023-08-10 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1673343A4 (en) * | 2003-10-08 | 2008-09-10 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS |
| DE102006030524A1 (de) * | 2006-07-01 | 2008-01-03 | Koch Transporttechnik Gmbh | Verfahren und Vorrichtung zur Beseitigung von lockerem Material auf wellenförmigen Oberflächen gestampfter Kohle für die Verkokung |
| CN101553232A (zh) * | 2006-09-14 | 2009-10-07 | 迪赛孚尔制药有限公司 | 用于治疗增殖性疾病的激酶抑制剂 |
| US8188113B2 (en) * | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| CN101528744A (zh) * | 2006-10-20 | 2009-09-09 | Irm责任有限公司 | 用于调节c-kit和pdgfr受体的组合物和方法 |
| CL2009000400A1 (es) * | 2008-02-22 | 2010-09-10 | Irm Llc | Compuestos heterociclicos derivados de 3-fenil-1,6- naftiridin-2-ona; moduladores de la actividad cinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastornos alergicos, trastornos autoinmunes, neoplasias, rechazo en trasplante de organos, entre otras. |
-
2012
- 2012-06-07 RU RU2014153920A patent/RU2664055C2/ru active
- 2012-06-07 EP EP17208408.9A patent/EP3366293B1/en active Active
- 2012-06-07 CN CN201910368784.6A patent/CN110403938A/zh active Pending
- 2012-06-07 MX MX2020005712A patent/MX2020005712A/es unknown
- 2012-06-07 HU HUE17208408A patent/HUE049958T2/hu unknown
- 2012-06-07 AU AU2012327210A patent/AU2012327210B2/en active Active
- 2012-06-07 LT LTEP17208408.9T patent/LT3366293T/lt unknown
- 2012-06-07 CN CN201280075113.7A patent/CN104902895B/zh active Active
- 2012-06-07 BR BR112014030577-3A patent/BR112014030577B1/pt active IP Right Grant
- 2012-06-07 SI SI201231785T patent/SI3366293T1/sl unknown
- 2012-06-07 PT PT172084089T patent/PT3366293T/pt unknown
- 2012-06-07 EP EP20161887.3A patent/EP3722296A3/en active Pending
- 2012-06-07 ES ES17208408T patent/ES2797252T3/es active Active
- 2012-06-07 WO PCT/US2012/041378 patent/WO2013184119A1/en active Application Filing
- 2012-06-07 DK DK17208408.9T patent/DK3366293T3/da active
- 2012-06-07 KR KR1020157000365A patent/KR101652229B1/ko active IP Right Grant
- 2012-06-07 EP EP12878321.4A patent/EP2858646B1/en active Active
- 2012-06-07 CN CN201910368783.1A patent/CN110433162A/zh active Pending
- 2012-06-07 CA CA2875970A patent/CA2875970C/en active Active
- 2012-06-07 PT PT128783214T patent/PT2858646T/pt unknown
- 2012-06-07 ES ES12878321.4T patent/ES2663605T3/es active Active
- 2012-06-07 MX MX2014015024A patent/MX2014015024A/es active IP Right Grant
- 2012-06-07 JP JP2015515992A patent/JP5883195B2/ja active Active
- 2012-06-07 RS RS20200633A patent/RS60406B1/sr unknown
- 2012-06-07 SG SG11201408133TA patent/SG11201408133TA/en unknown
- 2012-06-07 PL PL17208408T patent/PL3366293T3/pl unknown
- 2012-06-07 DK DK12878321.4T patent/DK2858646T3/en active
-
2014
- 2014-12-07 IL IL236110A patent/IL236110A/en active IP Right Grant
- 2014-12-09 PH PH12014502757A patent/PH12014502757B1/en unknown
-
2015
- 2015-10-15 HK HK15110134.9A patent/HK1209345A1/xx unknown
-
2018
- 2018-10-29 PH PH12018502294A patent/PH12018502294A1/en unknown
-
2020
- 2020-05-29 HR HRP20200864TT patent/HRP20200864T1/hr unknown
- 2020-06-10 CY CY20201100530T patent/CY1123377T1/el unknown
-
2022
- 2022-04-07 NO NO2022010C patent/NO2022010I1/no unknown
- 2022-04-07 FR FR22C1013C patent/FR22C1013I2/fr active Active
- 2022-05-03 LT LTPA2022008C patent/LTPA2022008I1/lt unknown
- 2022-05-09 HU HUS2200017C patent/HUS2200017I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR22C1013I2 (fr) | Dihydronaphtyridines et composés apparentés utiles comme inhibiteurs de kinases pour le traitement de maladies prolifératives | |
| FR19C1062I2 (fr) | Derives macrocycliques pour le traitement de maladies proliferatives | |
| IL267609B (en) | Beta protein inhibitors in combination with Janus kinase inhibitors for the treatment of proliferative diseases | |
| HK1210174A1 (en) | Serine threonine kinase inhibitors for the treatment of hyperproliferativediseases | |
| IL244492A0 (en) | Broton tyrosine kinase inhibitors | |
| HK1200449A1 (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases bub1 | |
| EP3019491A4 (en) | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | |
| PT3418281T (pt) | Pirazolo[1,5-a]pirimidinas úteis como inibidores da quinase atr para o tratamento de doenças de cancro | |
| EP2925740A4 (en) | INHIBITORS OF BRUTON TYROSINE KINASE | |
| HK1207861A1 (en) | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1 | |
| EP2858500A4 (en) | INHIBITORS OF BRUTON TYROSINE KINASE | |
| LT3386991T (lt) | Policikliniai junginiai, kaip brutono tirozinkinazės inhibitoriai | |
| EP2833886A4 (en) | SUBSTITUTED QUINOLINES AS INHIBITORS OF BRUTON TYROSINE KINASES | |
| HK1210616A1 (en) | Process for the preparation of c-fms kinase inhibitors c-fms | |
| HK1223832A1 (zh) | 用於癌症治療的激酶抑制劑 | |
| IL238165A0 (en) | Methods for the detection of compounds for the treatment of depression and other related diseases | |
| HK1222386A1 (zh) | 作爲詹納斯激酶的抑制劑的 -氰基甲基酰胺 | |
| AU2012901199A0 (en) | Kinase inhibitors for the Treatment of Cancer |